Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 0.4% on Insider Selling

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) were down 0.4% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $569.49 and last traded at $571.69. Approximately 353,321 shares changed hands during trading, a decline of 82% from the average daily volume of 1,947,027 shares. The stock had previously closed at $574.14.

Specifically, CFO Jamie Samath sold 94 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the sale, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at approximately $1,502,019.30. The trade was a 3.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Mizuho upped their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. The Goldman Sachs Group set a $604.00 target price on Intuitive Surgical in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating and set a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Robert W. Baird raised their price objective on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Leerink Partners boosted their target price on shares of Intuitive Surgical from $490.00 to $548.00 in a report on Monday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Trading Up 1.3 %

The firm’s 50-day moving average price is $549.32 and its 200 day moving average price is $507.50. The company has a market cap of $206.65 billion, a price-to-earnings ratio of 93.28, a P/E/G ratio of 5.19 and a beta of 1.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at about $26,000. Godsey & Gibb Inc. grew its stake in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new stake in Intuitive Surgical in the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. acquired a new position in Intuitive Surgical during the 4th quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP bought a new position in Intuitive Surgical in the third quarter worth approximately $38,000. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.